597 filings
Page 9 of 30
8-K
tm3pq68r2
3 Mar 21
Regulation FD Disclosure
7:01am
424B5
3a4hzb2ly7rd5tk
28 Jan 21
Prospectus supplement for primary offering
4:11pm
8-K
rjicbyxzyfqlp1n2r9s
27 Jan 21
Catalyst Biosciences Announces Pricing of Public Offering of Common Stock
5:23pm
8-K
fhewo g5dzbj40
26 Jan 21
Regulation FD Disclosure
4:16pm
8-K
fdb g2eil2
26 Jan 21
Catalyst Biosciences Announces Proposed Public Offering of Common Stock
4:12pm
424B5
u8v187 25rz
26 Jan 21
Prospectus supplement for primary offering
4:07pm
8-K
nyss frxo5pqahe
14 Dec 20
Regulation FD Disclosure
11:50am
8-K
h2l2kgn2l2iaowdn3
2 Dec 20
Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Hemophilia A or B with Inhibitors
4:33pm
8-K
v8z401q3nco
17 Nov 20
Regulation FD Disclosure
6:07am
8-K
6xqurknqph027abs6h
5 Nov 20
Catalyst Biosciences Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update
8:11am
8-K
l4mvm1bsalgn
17 Sep 20
Regulation FD Disclosure
4:52pm
8-K
3ia2qkhgdlr6aho
6 Aug 20
Catalyst Biosciences Reports Second Quarter 2020 Operating & Financial Results and Provides a Corporate Update
4:32pm
S-8
fvvupvy 9o
6 Jul 20
Registration of securities for employees
5:23pm
8-K
d5rkf u7kizpkl
19 Jun 20
Catalyst Biosciences Announces Proposed Public Offering of Common Stock
4:26pm
424B5
tqw8oo2fjht2ns5x
19 Jun 20
Prospectus supplement for primary offering
4:23pm
8-K
icq5i5l1lp909fpdgmc
18 Jun 20
Regulation FD Disclosure
4:02pm
8-K
pathr wjdjvi2eb9p5
17 Jun 20
Other Events
4:08pm
424B5
9l6cq4a 9tnpwi2226p
17 Jun 20
Prospectus supplement for primary offering
4:05pm